ConductScience.org, home

Paper17501757

Therapeutic issues in HIV/HCV-coinfected patients.

Sulkowski MS and 1 other. J Viral Hepat, 2007. Cited by 64 papers, by iCite.

Cite this record

ConductScience Library. Therapeutic issues in HIV/HCV-coinfected patients. Papers, record 17501757. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17501757

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic issues in HIV/HCV-coinfected patients.
PubMed
Journal
J Viral Hepat
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
64
iCite
Relative citation ratio, by iCite
1.55
iCite
Revised in PubMed
2024-05-10
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sulkowski MSM S
2Benhamou YY

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
HIVMajor topic
HIV InfectionsMajor topic
Hepatitis CMajor topic
Interferon-alphaMajor topic
Polyethylene GlycolsMajor topic
RibavirinMajor topic
Anemia
Chemical and Drug Induced Liver Injury
Disease Progression
Drug Therapy, Combination
Humans
Interferon alpha-2
Leukopenia
Liver Cirrhosis
Liver Transplantation
Mitochondrial Diseases
Recombinant Proteins
Treatment Outcome

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R37 DA013806NIDA NIH HHSUnited StatesR01DA013806PubMed and NIHNIH RePORTER
DA-13806NIDA NIH HHSUnited StatesR01DA013806PubMed and NIHNIH RePORTER
DA-16065NIDA NIH HHSUnited StatesR01DA016065PubMed and NIHNIH RePORTER
R01 DA016065NIDA NIH HHSUnited StatesR01DA016065PubMed and NIHNIH RePORTER
R01 DA013806NIDA NIH HHSUnited StatesR01DA013806PubMed and NIHNIH RePORTER
R37DA013806NIHNIH RePORTER

Download CSV of grants

References92

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115828854Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.Clin Pharmacokinet2005https://conductscience.org/library/papers/15828854PubMed
211197250Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.Am J Gastroenterol2001https://conductscience.org/library/papers/11197250PubMed
312095384Hepatitis C and progression of HIV disease.JAMA2002https://conductscience.org/library/papers/12095384PubMed
415282352Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.N Engl J Med2004https://conductscience.org/library/papers/15282352PubMed
512879995Antiretroviral-associated liver injury.Clin Liver Dis2003https://conductscience.org/library/papers/12879995PubMed
63435108
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.
Antimicrob Agents Chemother1987https://conductscience.org/library/papers/3435108PubMed
716207569HIV and liver diseases: recent clinical advances.Clin Liver Dis2005https://conductscience.org/library/papers/16207569PubMed
815117326Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.J Viral Hepat2004https://conductscience.org/library/papers/15117326PubMed
911786975Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.Hepatology2002https://conductscience.org/library/papers/11786975PubMed
1015972867Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.N Engl J Med2005https://conductscience.org/library/papers/15972867PubMed
1110632283Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.JAMA2000https://conductscience.org/library/papers/10632283PubMed
128627819Characterization of long-term cultures of hepatitis C virus.J Virol1996https://conductscience.org/library/papers/8627819PubMed
1315057903Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.Hepatology2004https://conductscience.org/library/papers/15057903PubMed
1415219554HIV and hepatitis C virus co-infection.Lancet Infect Dis2004https://conductscience.org/library/papers/15219554PubMed
1511214134Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.Lancet2001https://conductscience.org/library/papers/11214134PubMed
169371165Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.Lancet1997https://conductscience.org/library/papers/9371165PubMed
1715456081Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.Antivir Ther2004https://conductscience.org/library/papers/15456081PubMed
1810669367Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.J Infect Dis2000https://conductscience.org/library/papers/10669367PubMed
199225024Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma.J Gen Virol1997https://conductscience.org/library/papers/9225024PubMed
209174176Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9174176PubMed

See all 92 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMIDTitleJournalYearIn PapersSource
41126156Hepatitis B vaccination status and associated factors among people living with HIV in Gulu, Uganda: a cross-sectional study.BMC Public Health2025https://conductscience.org/library/papers/41126156PubMed
36844142Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.World J Gastroenterol2023https://conductscience.org/library/papers/36844142PubMed
35054088Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection.J Clin Med2022https://conductscience.org/library/papers/35054088PubMed
34943573Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience.Diagnostics (Basel)2021https://conductscience.org/library/papers/34943573PubMed
28697809Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users.Virol J2017https://conductscience.org/library/papers/28697809PubMed
27830997Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.Pathog Glob Health2016https://conductscience.org/library/papers/27830997PubMed
2702583512 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.Clin Infect Dis2016https://conductscience.org/library/papers/27025835PubMed
26511293Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.J Viral Hepat2016https://conductscience.org/library/papers/26511293PubMed
25769097Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.Eur J Gastroenterol Hepatol2015https://conductscience.org/library/papers/25769097PubMed
25705565Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.J Clin Cell Immunol2014https://conductscience.org/library/papers/25705565PubMed
25580050Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.Dis Markers2014https://conductscience.org/library/papers/25580050PubMed
25007250CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.PLoS One2014https://conductscience.org/library/papers/25007250PubMed
24650094Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.BMC Infect Dis2014https://conductscience.org/library/papers/24650094PubMed
23691197The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting.PLoS One2013https://conductscience.org/library/papers/23691197PubMed
21606539The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women.J Infect Dis2011https://conductscience.org/library/papers/21606539PubMed
21045598Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.J Acquir Immune Defic Syndr2010https://conductscience.org/library/papers/21045598PubMed
20555019Adjuvant high-dose interferon-{alpha} for resected melanoma in a patient with HIV infection.Oncologist2010https://conductscience.org/library/papers/20555019PubMed
20523729High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China.PLoS One2010https://conductscience.org/library/papers/20523729PubMed
20142333Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.Oncologist2010https://conductscience.org/library/papers/20142333PubMed
19853480Hepatitis C treatment experiences and decision making among patients living with HIV infection.J Assoc Nurses AIDS Care2010https://conductscience.org/library/papers/19853480PubMed

See all 25 cited byDownload CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17501757

GET https://conductscience.org/api/papers/v1/17501757/references?page=2